Accelerate the Cure
Into the world—Welcome Bexobrutideg!
We recently wrote about a new type of drug—a BTK degrader— that emerged in 2024, for phase one trials at Nurix Therapeutics and BeOne. The Nurix trial earned FDA fast-track status in December. In a short three months since then, NX-5948 has earned FDA’s Orphan Status designation. This is a big deal.
This orphan drug for WM has a new assigned name that follows international drug-naming conventions. Welcome Bexobrutideg! “Bexo” represents a unique identifier within this new class of BTK degraders, while “deg” represents the novel degradation mechanism of the drug. The central stem, “bruti”, is a reference to its Bruton’s tyrosine kinase (BTK) target.
Orphan status is reserved for promising therapies for rare diseases affecting fewer than 200,000 US residents. Nurix receives tax credits and seven years of market exclusivity to support the trial effort, which can take longer to enroll rare disease populations.
Contact information for 35 study sites can be found here.
The pipeline to a WM cure: IWMF donations + basic research + clinical trials + patient and physician knowledge.
Are you a patient with Waldenström Macroglobulinemia (WM) who has previously received a Bruton’s tyrosine kinase (BTK) inhibitor such as ibrutinib, acalabrutinib, or zanubrutinib? Are you currently looking for an alternative treatment option after your disease worsened or you experienced significant side effects from the BTK inhibitor?